Your session is about to expire
← Back to Search
Dexamethasone for Post-Embolization Pain in Fibroids (Dex-Fib Trial)
Dex-Fib Trial Summary
This trial is investigating whether giving steroids through the uterine arteries during fibroid embolization can help reduce pain, nausea, vomiting, and weakness afterwards.
Dex-Fib Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDex-Fib Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 4 trial • 122 Patients • NCT01474915Dex-Fib Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am eligible for a procedure to treat my painful fibroids.You cannot have an angiography due to medical reasons.I have diabetes or am considered pre-diabetic.I am able to make my own medical decisions.I am currently taking daily steroids for a condition.I am eligible for a procedure to treat my painful fibroids.
- Group 1: Saline Arm
- Group 2: Dexamethasone Arm
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the medical requirements to participate in this trial?
"The team conducting this clinical trial is looking for 82 individuals, all between the ages of 20 and 50, who currently have leiomyoma. Furthermore, it is imperative that potential participants also fit the following description: women who would be good candidates for uterine fibroid embolization due to their symptomatic fibroids."
To what purpose is Dexamethasone most often administered?
"Dexamethasone is frequently used to treat ophthalmia and sympathetic. Other potential conditions that this medication can help manage include branch retinal vein occlusion and macular edema."
Is this research only open to seniors, or will younger patients be able to enroll as well?
"The focus of this research is to recruit individuals who are between 20-50 years old."
How many patients are you testing this medication on?
"That is correct, the online information hosted on clinicaltrials.gov specifies that this trial is open for recruitment. It was originally posted on 1/25/2021, with the most recent update being on 3/10/2022. The trial has 82 spots open for participants at 1 location."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger